Identifying mechanisms that improve immune checkpoint inhibitor efficacy in non-small cell lung cancer

确定提高非小细胞肺癌免疫检查点抑制剂疗效的机制

• 批准号: 457478
• 负责人: Sorin Mark
• 金额: $ 10.93万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-11-01 至 2024-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=457478&lang=en
• 关键词: Cancer; Immunology; Immunotherapy; Lung; Resistance; Tumour Immune Microenvironment

Lung cancer is the greatest cause of cancer-related death worldwide, accounting for about 25% of all cancer-related fatalities. Indeed, more people die from lung cancer than breast, colon and pancreatic cancer combined. Non-small cell lung cancer, a subty

肺癌是全球癌症相关死亡的最大原因，约占所有癌症相关死亡的25%。事实上，死于肺癌的人数比乳腺癌、结肠癌和胰腺癌的总和还要多。非小细胞肺癌是一种